Please login to the form below
Oseni
This page shows the latest Oseni news and features for those working in and with pharma, biotech and healthcare.
Forest Labs agrees $1.46bn deal to buy Furiex
Furiex also has a stable of marketed drugs for diabetes including Nesina (alogliptin) and fixed-dose combination therapies Oseni/Liovel (alogliptin/pioglitazone) and Kazan (alogliptin/metformin), which are sold by Takeda,
Latest news
-
FDA investigates pancreas risk of diabetes drugs
Newer DPP-4 inhibitors Tradjenta (linagliptin) from Boehringer Ingelheim and Takeda's alogliptin-based medicines (Nesina, Kazano and Oseni) are also affected.
-
Takeda gets FDA approval for alogliptin franchise in diabetes
Comprises Nesina, Oseni and Kazano. Takeda was celebrating at the end of last week after the FDA granted approval to three of its diabetes drug candidates. ... The US agency approved Takeda's DPP-4 inhibitor Nesina (alogliptin) - along with two
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Featured jobs
-
Vice President
-
Competitive Salary Offered
-
Consultant
-
competitive salary
- Account Director or Senior Account Director
-
Salary TBC
-
Principal Medical Writer
-
£48 - 58, 000 according to skills and experience benefits
- Director of Scientific Services, Medical Communications, Six fig...
-
Six figure salary
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Account Manager– Medical Communications
-
(Negotiable - depending on experience)
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
Subscribe to our email news alerts
- Lilly will aim for one $1bn-$5bn deal per quarter in 2020
- Moving annual total (MAT)
- Novartis gets EU approval for multiple sclerosis therapy Mayzent
- Immuno-oncology, personalised medicine continues to drive pharma sector
- FDA delays decision on Intercept's NASH drug by three months
- Roche’s SMA treatment risdiplam hits another clinical target
- New coronavirus sees drug developers scramble to develop a vaccine
- Sanofi completes acquisition of immuno-oncology specialist Synthorx
- Roche's checkpoint inhibitor fails pivotal urothelial cancer trial
- Epizyme wins FDA approval for epithelioid sarcoma treatment
- Pharma Brand Planners' Blog (Part 8)
- Happy Chinese New Year 2020 - The Year of The Rat
PMHub
CSafe Global
CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...
Latest intelligence
- Happy Chinese New Year 2020 - The Year of The Rat
- A fond farewell to The Year of the Pig...
- White Paper for download - Explaining the price of your product
- In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
- OPEN Health expands offering with the launch of a new Learning & Development specialist team
- Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Quick links
Infographics
